• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Neptune Reschedules Release of Fourth Quarter and Full Year 2022 Financial Results and Date of Earnings Call

    6/29/22 5:03:00 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NEPT alert in real time by email

    LAVAL, QC, June 29, 2022 /PRNewswire/ - Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT) (TSX:NEPT), a diversified and fully integrated health and wellness company focused on plant-based, sustainable and purpose-driven lifestyle brands, today announced a delay of the filing of its annual financial statements (the "2022 Financial Statements") and related management's discussion and analysis beyond the prescribed deadline of June 29, 2022.

    The delay in the completion of the Company's financial statements relates principally to the complexity of the conversion of the Company's financial statements from IFRS to U.S. GAAP. Neptune expects to file its fourth quarter and full-year 2022 financial results in the coming days, with filing timing to be provided once confirmed by auditors.  Following the release of its financial results, the Company will host a conference call to discuss financials and provide a business update. Details of the time and date for the rescheduled earnings call will be announced in due course.

    Management and the audit committee, will continue to work towards the completion of the annual financial statements, and cooperate with its auditors to provide all necessary information to complete the audit as soon as possible.

    In addition to the foregoing, pursuant to National Instrument 51-102 – Continuous Disclosure Obligations ("NI 51-102"), namely Part 4 of NI 51-102, as an "SEC Issuer", given that Neptune will be filing the 2022 Financial Statements which will, for the first time, be prepared in accordance with U.S. GAAP as a result of the Company having lost its foreign private issuer status, the Company is required to re-file its previously filed interim financial reports that have been filed since its last filing of annual financial statements for its fiscal year ended March 31, 2021, which include: (i) the three-month periods ended June 30, 2021 and 2020, (ii) the three and six-month periods ended September 30, 2021 and 2020; and (iii) the three and nine-month periods ended December 31, 2021 and 2020 (collectively, the "Restated Filings"), with such Restated Filings to be prepared and refiled in accordance with U.S. GAAP. The Restated Filings are required to be refiled at the same time as the filing of the 2022 Annual Financial Statements. Despite substantial efforts, the Company is also currently not in a position to file the Restated Filings by the prescribed filing date of June 29, 2022 as a result of the longer than anticipated time required to restate the Restated Filings under U.S. GAAP.

    As a result of the foregoing, being the delay in filing of the 2022 Financial Statements and the refiling of the Restated Filings, the Company has applied to the applicable Canadian securities regulatory authorities for a temporary management cease trade order ("MCTO"), but such order has not yet been obtained as of the date hereof and there are no assurances such order will be obtained in a timely manner, or at all. The Company intends to satisfy the provisions of the alternative information guidelines in accordance with National Policy 12-203 – Management Cease Trade Orders by issuing bi-weekly status reports in the form of news releases. The applicable Canadian securities regulatory authorities may issue a general cease trade order against the Company for failure to file the 2022 Financial Statements and/or the Restated Filings within the prescribed time period or sooner if the Company fails to file its status reports during the prescribed time limits. If the MCTO is not obtained, a general cease trade order may also be issued. 

    The 2022 Annual Statements and the Restated Filings are expected to be filed as soon as practicable within the coming days, but no later than on or before July 13, 2022.  With respect to the Restated Filings, other than the conversion into U.S. GAAP, the Company does not expect any other changes to be made to the previously filed interim financial reports, which were previously prepared in accordance with IFRS and are all currently available under the Company's SEDAR and EDGAR profiles at www.sedar.com and www.sec.gov, respectively.

    About Neptune Wellness Solutions Inc.

    Headquartered in Laval, Quebec, Neptune is a diversified health and wellness company with a mission to redefine health and wellness.  Neptune is focused on building a portfolio of high quality, affordable consumer products in response to long-term secular trends and market demand for natural, plant-based, sustainable and purpose-driven lifestyle brands. The Company utilizes a highly flexible, cost-efficient manufacturing and supply chain infrastructure that can be scaled to quickly adapt to consumer demand and bring new products to market through its mass retail partners and e-commerce channels. For additional information, please visit: https://neptunewellness.com/.

    Disclaimer – Safe Harbor Forward–Looking Statements

    Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Neptune Wellness Solutions to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.

    Neither NASDAQ nor the Toronto Stock Exchange accepts responsibility for the adequacy or accuracy of this release.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/neptune-reschedules-release-of-fourth-quarter-and-full-year-2022-financial-results-and-date-of-earnings-call-301578330.html

    SOURCE Neptune Wellness Solutions Inc.

    Get the next $NEPT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NEPT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NEPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Neptune Securities Settlement Fund sold $13,601 worth of shares (200,300 units at $0.07), decreasing direct ownership by 25% to 1,048,334 units (SEC Form 4)

    4 - Neptune Wellness Solutions Inc. (0001401395) (Issuer)

    4/30/24 12:01:00 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Securities Settlement Fund sold $35,224 worth of shares (81,814 units at $0.43), decreasing direct ownership by 7% to 1,671,302 units (SEC Form 4)

    4 - Neptune Wellness Solutions Inc. (0001401395) (Issuer)

    3/6/24 11:04:07 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Securities Settlement Fund sold $187,949 worth of shares (247,604 units at $0.76), decreasing direct ownership by 12% to 1,778,380 units (SEC Form 4)

    4 - Neptune Wellness Solutions Inc. (0001401395) (Issuer)

    11/30/23 5:26:53 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NEPT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neptune Appoints Interim President and CEO and Interim COO

    LAVAL, QC / ACCESSWIRE / March 8, 2024 / Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), today announced the Company's Board of Directors has named Board member Michael De Geus Interim President and Chief Executive Officer, effective immediately. Mr. De Geus has served as an integral member of the previously disclosed Restructuring Committee of the Board of Directors following the furlough and departure of Michael Cammarata, who served as President and Chief Executive Officer since 2019. Additionally, the Company's Board of Directors has named Cedrick Billequey, currently General Manager of Neptune's subsidiary Biodroga Nutraceuticals, Inc. ("Biodroga"), Interim C

    3/8/24 8:30:00 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Announces Decision of Nasdaq Hearings Panel To Delist Common Shares

    LAVAL, QC / ACCESSWIRE / March 6, 2024 / Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), today announced an update on the status of its appeal against the determination of the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") to delist the Company's common shares ("Common Shares").As previously disclosed, the Company had been notified by Nasdaq on November 30, 2023 that it was not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market (NASDAQ Listing Rule 5550(a)(2)), as the bid price for the Common Shares on Nasdaq closed below US$1.00 for 30 consecutive trading days and that it was not in comp

    3/6/24 8:30:00 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Announces Michael Cammarata's Resignation Effective February 23, 2024

    LAVAL, QC / ACCESSWIRE / March 4, 2024 / Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), today announced that Michael Cammarata has resigned from his role as President and Chief Executive Officer effective February 23, 2024. We thank Michael for his service and wish him best of luck in his future endeavors.About Neptune Wellness Solutions Inc.Neptune is a consumer-packaged goods company that aims to innovate health and wellness products. Founded in 1998 and headquartered in Laval, Quebec with a United States headquarters in Jupiter, Florida, the company focuses on developing a portfolio of high-quality, affordable consumer products that align with the latest marke

    3/4/24 8:31:00 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NEPT
    SEC Filings

    View All

    Neptune Wellness Solutions Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Neptune Wellness Solutions Inc. (0001401395) (Filer)

    5/6/24 2:26:26 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25-NSE filed by Neptune Wellness Solutions Inc.

    25-NSE - Neptune Wellness Solutions Inc. (0001401395) (Subject)

    4/25/24 9:09:07 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Wellness Solutions Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

    8-K - Neptune Wellness Solutions Inc. (0001401395) (Filer)

    4/12/24 5:02:21 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NEPT
    Leadership Updates

    Live Leadership Updates

    View All

    Neptune Appoints Interim President and CEO and Interim COO

    LAVAL, QC / ACCESSWIRE / March 8, 2024 / Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), today announced the Company's Board of Directors has named Board member Michael De Geus Interim President and Chief Executive Officer, effective immediately. Mr. De Geus has served as an integral member of the previously disclosed Restructuring Committee of the Board of Directors following the furlough and departure of Michael Cammarata, who served as President and Chief Executive Officer since 2019. Additionally, the Company's Board of Directors has named Cedrick Billequey, currently General Manager of Neptune's subsidiary Biodroga Nutraceuticals, Inc. ("Biodroga"), Interim C

    3/8/24 8:30:00 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Reports Fiscal Third Quarter 2024 Financial Results

    LAVAL, QC / ACCESSWIRE / February 16, 2024 / Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), a consumer-packaged goods company focused on plant-based, sustainable and purpose-driven lifestyle brands, today announced its financial and operating results for its fiscal third quarter 2024 ending December 31, 2023.Recent Business HighlightsAnnounced the appointment of Stifel Nicolaus Canada Inc. ("Stifel") to act as exclusive financial advisor to the Company's organic baby food and toddler brand, Sprout Foods Inc. ("Sprout Organics"), providing financial advisory, investment banking services, and strategic advice regarding the review of divestiture alternatives related

    2/16/24 5:35:00 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Retains Stifel to Explore Strategic Alternatives for Sprout Organics

    LAVAL, QC / ACCESSWIRE / January 24, 2024 / Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), a consumer-packaged goods company focused on plant-based, sustainable and purpose-driven lifestyle brands, today announced the appointment of Stifel Nicolaus Canada Inc. ("Stifel") to act as exclusive financial advisor to the Company's organic baby food and toddler brand, Sprout Foods Inc. ("Sprout Organics"), providing financial advisory, investment banking services, and strategic advice regarding the review of divestiture alternatives related to Sprout Organics.Stifel brings a wealth of experience and expertise in the financial sector, having successfully facilitated nume

    1/24/24 9:00:00 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NEPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Neptune Wellness Solutions Inc. (Amendment)

    SC 13G/A - Neptune Wellness Solutions Inc. (0001401395) (Subject)

    2/12/24 6:48:47 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Neptune Wellness Solutions Inc. (Amendment)

    SC 13G/A - Neptune Wellness Solutions Inc. (0001401395) (Subject)

    1/2/24 2:02:04 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Neptune Wellness Solutions Inc.

    SC 13D - Neptune Wellness Solutions Inc. (0001401395) (Subject)

    10/17/23 11:57:17 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NEPT
    Financials

    Live finance-specific insights

    View All

    Neptune Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results

    Consolidated revenues for fiscal 2023 totaled $52.6 million, an increase of $3.8 million or 7.8% as compared to $48.8 million for fiscal 2022 Q4 net sales $12.1 million, up 5% from last year's $11.5 million Sprout maintained a top 3 brand position on Amazon in fiscal 2023 and strong sales levels in all periods nationally1 Sprout was available in 90% of footprint the Organic Baby Food market across all 50 U.S. states and Canada Company to host a conference call at 5:00 p.m. (Eastern Time) on Tuesday, July 18, 2023 LAVAL, QC, July 17, 2023 /PRNewswire/ - Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), a consumer-packaged goods company focused on plant-based, sustai

    7/17/23 5:38:00 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune to Report Fiscal Third Quarter 2023 Financial Results on March 30, 2023

    Company to host a conference call at 5:00 p.m. (Eastern Time) LAVAL, QC, March 30, 2023 /PRNewswire/ - Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), a consumer-packaged goods company focused on plant-based, sustainable and purpose-driven lifestyle brands, announced today that it will report its financial results for the third quarter of fiscal 2023 after the market close on Thursday, March 30, 2023. The Company will host a conference call at 5:00 p.m. (Eastern Time) today, Thursday, March 30, 2023, to discuss these results. The conference call wil

    3/30/23 11:28:00 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Announces Receipt of NASDAQ Notification

    LAVAL, QC, Feb. 24, 2023 /PRNewswire/ - Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT) ), a consumer-packaged goods company focused on plant-based, sustainable and purpose-driven lifestyle brands, today announced that the Company has received written notification from the Listing Qualification Department of the Nasdaq Stock Market LLC on February 23, 2023, notifying the Company that it is no longer in compliance with Nasdaq Listing Rule 5250(c)(1), as a result of Neptune not having timely filed its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2022 with the U.S. Securities and Exchange Commission.  

    2/24/23 4:05:00 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care